Abstract
Background Effectiveness of mRNA vaccinations against Omicron among US veterans is unknown.
Objectives To estimate mRNA COVID-19 vaccine effectiveness (VE) as measured by risk of SARS-CoV-2 infection.
Design, Setting, and Participants This matched test–negative case-control study was conducted using SARS-CoV-2 test results at Veterans Health Administration sites from December 1, 2021, to December 31, 2021. VE against SARS-CoV-2 infection and COVID-19–related hospitalization and death were estimated using electronic health records from veterans who routinely sought care at a VHA facility and had a test result positive for SARS-CoV-2 (cases) or negative for SARS-CoV-2 (controls). Data were analyzed from December 1, 2021 to January 14, 2022.
Exposures Vaccination status, defined as number of mRNA vaccine doses (1, 2, 3 or more) as the primary explanatory variable, at time of test.
Main Outcomes and Measures The main outcome of interest was a positive result for SARS-CoV-2 on a polymerase chain reaction or antigen test. Secondary outcomes included COVID-19–related hospitalization and death, defined by discharge data and proximity of event to positive test result. VE was estimated from odds ratios for SARS-CoV-2 infection with 95% CIs.
Results VE for those who have received a mRNA vaccine booster is 77% (95%, 75 to 79) against Delta while 62% (95%, 59 to 65) against Omicron infection, 91% (95%, 85 to 94) against COVID-related hospitalization with better VE against Omicron, and 96% (95%, 91 to 98) against COVID-related death with no discernable difference between Omicron and Delta. However, without a booster, VE against COVID-related death decreases to 76% (95%, 62 to 85).
Conclusions Although Omicron is highly contagious and more likely to result in breakthrough infections against the current mRNA vaccines, a mRNA vaccine booster is still effective against severe COVID-related outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was funded by the U.S. Department of Veterans Affairs (VA) Office of Rural Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional review board of the Department of Veterans Affairs Medical Center in White River Junction, Vermont, and was granted an exemption for consent because it was deemed impractical.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclaimer: This article represents the author’s best judgement and should not bind or obligate the VA or any other institution.
Conflict of Interest Declaration: YYX acknowledges having received funding from Pfizer for other research projects but not this one.
Data Availability
The data are available upon request to: Clinical Epidemiology Program Veterans Affairs Medical Center 215 North Main Street White River Junction, VT 05009
